The combined images detail fields related to **Adjuvant Chemotherapy** and its associated effects, implementation, and outcomes. Here's a structured explanation:

### **General Information**

1. **Patientennummer**:
   * Unique identifier for the patient.

### **Radiotherapy and Chemotherapy**

1. **Radiotherapie**:
   * Indicates whether radiotherapy was used.
2. **Strahlenmenge in Gray**:
   * Total radiation dose administered (measured in Gray).
3. **Chemotherapie**:
   * Indicates whether chemotherapy was part of the treatment.
4. **Anzahl der Zyklen**:
   * Number of chemotherapy cycles administered.

### **Chemotherapeutic Agents**

1. **5-Fluorouracil**:
   * Common chemotherapy drug.
2. **Capecitabin**:
   * Oral prodrug of 5-Fluorouracil.
3. **Oxaliplatin**, **Cisplatin**, **Carboplatin**:
   * Platinum-based drugs used for various cancers.
4. **Epirubicin**, **Doxorubicin**:
   * Anthracycline drugs for breast and other cancers.
5. **Gemcitabin**, **Docetaxel**, **Paclitaxel**, **Irinotecan**:
   * Various chemotherapy drugs for pancreatic, breast, ovarian, and colorectal cancers.
6. **Sorafenib**:
   * Targeted therapy for liver and kidney cancers.
7. **Folinsäure**:
   * Enhances 5-Fluorouracil efficacy.
8. **Andere Chemotherapeutika I, II, III**:
   * Other unspecified chemotherapy agents.

### **Interventional Therapies**

1. **TACE (Transarterial chemoembolization)**:
   * Localized liver cancer treatment.
2. **RFA (Radiofrequency ablation)**:
   * Used to destroy tumors.
3. **Photodynamische Therapie (PDT)**:
   * Light-based cancer treatment.
4. **TACE Zyklen**, **RFA Zyklen**, **PDT Zyklen**:
   * Number of cycles for respective therapies.

### **Treatment Outcomes**

1. **Stabiler Verlauf**:
   * Stable disease (no progression or shrinkage).
2. **Progression**:
   * Disease progression.
3. **Regression**:
   * Tumor shrinkage.
4. **Remission**:
   * Absence of detectable cancer.

### **Tumor Board Recommendations**

1. **Tumorboardbeschluss**:
   * Decision made by the tumor board.
2. **Empfehlungen TuBo**:
   * Recommendations from the tumor board.
3. **Umsetzung TuBo**:
   * Implementation of tumor board decisions.

### **Dosage Adjustments**

1. **Dosis nach KOF**:
   * Dose calculated by body surface area (Körperoberfläche).
2. **Primäre Dosisreduktion**:
   * Initial dose reduction.
3. **Dosisreduktion im Verlauf**:
   * Dose reduction during treatment.

### **Side Effects**

1. **Nebenwirkung der CX**:
   * Side effects of chemotherapy.
2. **Emesis**:
   * Vomiting.
3. **Diarrhoe**:
   * Diarrhea.
4. **Alopezie**:
   * Hair loss.
5. **Hans-Fuß-Syndrom**:
   * Hand-foot syndrome.
6. **KM-Depression**:
   * Bone marrow depression.
7. **Neurotoxizität**:
   * Neurological toxicity.
8. **Ototoxizität**:
   * Hearing loss or damage.
9. **AZ Verschlechterung**:
   * General condition deterioration.
10. **Sonstige Nebenwirkungen**:
    * Other side effects.
11. **Sonstige Nebenwirkungen Text**:
    * Text field for additional side effects.

### **Performance Status**

1. **ECOG-Stadium**:
   * ECOG performance status (patient’s functional ability).
2. **Karnofsky-Index (%)**:
   * Functional status percentage.

### **Molecular Markers**

1. **HER-2 Status**:
   * HER-2 receptor status, relevant in breast cancer.
2. **Mikrosatelliten**:
   * Microsatellite instability.

### **Treatment Implementation**

1. **Umsetzung Chemotherapie ungewiss**:
   * Uncertain implementation of chemotherapy.

This structured information tracks chemotherapy treatments, their implementation, outcomes, side effects, and adjustments to ensure personalized and effective patient care.